NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

My source regarding the Agenus efficacy must have been primarily their most recent webcast from the 26th Annual Oppenheimer Healthcare Conference. Starting from 14:30 they talk about the new trial for Prophage for GBM in planning.

What they say is a little different from what I remembered. They say the efficacy that they have seen allows them to move to a potential registration trial without changes for half of the patients. They say for the other half they want to add a checkpoint modulator.

They don't say explicity that they are basing this on the results of the phase 2. They don't say explicitly that the two patient group (halves) coincide with Temador response. And they don't say explicitly that they are talking about a phase 3 trial. Maybe it is a phase 2/3 trial... . They just say it will be a potential registration trial and likely take 2 years.

They don't give efficacy numbers in the webcast. Sounds like we will hear numbers soon. Perhaps they will also clarify what the characteristics are for the half of patients that did not respond well. In the webcast they only say that they think they can identify those patients apriori.

I am not currently invested in Agenus in spite of their many interesting programs. As far as I know they do not have anything imminent in the pipeline, which for me is a requirement.